Skip to content

Effect of Ayurvedic Treatment Regimen in COVID-19 Patients

A Clinical Evaluation of Efficacy of Ayurvedic treatment regimen as an Add-on therapy with Modern Medicine in COVID 19 - A Randomized, Multi-center, Single Blind, Prospective Clinical Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028437
Enrollment
380
Registered
2020-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: 1. Bilwadi Yog 2. Kantakaryavaleha 3. Shadangodak: 1. Bilwadi Yog - 1 gm BID 2. Kantakaryavaleha - 3 gm BID 3. Shadangodak - 40 ml BID Total Duration of the Therapy - 15 Days Contro

Sponsors

Ministry of AYUSH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All hospitalized cases above 18 years of age, clinically diagnosed with corona virus disease 2019 and presenting with mild to moderate signs and symptoms of COVID-19, quarantined at identified hospital set up. 2. Participants who can take medicines orally. 3. Patients willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Cases of severe vomiting which would affect oral administration of medicine difficult. 2. Cases of respiratory failure and requiring mechanical ventilation. 3. Combined organ failure requiring ICU monitoring. 4. Pregnant and lactating women. 5. Subjects having an active malignancy. 6. Subjects giving history of significant cardiovascular event 7. Subjects having a chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 8. Subjects having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes. 9. Any other condition, which as per the investigator would jeopardize the outcome of the trial.

Design outcomes

Primary

MeasureTime frame
1. Clinical cure rate: Time to negative conversion of severe acute respiratory syndrome corona-virus 2 (defined as viral load of respiratory specimen negative for two consecutive times when tested in an interval of two days)Timepoint: 3 Months

Secondary

MeasureTime frame
1. Length of stay in hospital 2. Duration of fever and respiratory symptoms 3. Improvement in hematological and laboratory parameters (Hs-CRP, ESR, TC, DC, Absolute lymphocyte count, LFT, RFT, IL-6, Ig E, Ig-G,Ig-M, LDH, Creatine Kinase, Platelet count), 4. Frequency of ADR/AE 5. Number of cases that required oxygen therapy during the intervention.Timepoint: 3 Months

Countries

India

Contacts

Public ContactDr Milind B Nikumbh

Government Ayurved College, Jalgaon

drnikumbh@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026